Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:608. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Collaborators. GDaIIaP. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 19902015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545602. <\/p>\n
Article Google Scholar <\/p>\n
Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:63149. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:64455. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs. 2003;63:163777. <\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016;56:1093106. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Burch R. Preventive migraine treatment. Continuum. 2021;27:61332. <\/p>\n
PubMed Google Scholar <\/p>\n
Wu JW, Yang CP. 2022 Taiwan Guidelines for Preventive Treatment of Migraine. Acta Neurol Taiwan. 2022;31:164202. <\/p>\n
Google Scholar <\/p>\n
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of. Neurol Am Headache Soc Neurol 2012;78:133745. <\/p>\n
CAS Google Scholar <\/p>\n
Kowalska M, Prendecki M, Piekut T, Kozubski W, Dorszewska J. Migraine: Calcium Channels and Glia. Int J Mol Sci. 2021;22:2688. <\/p>\n
Di Stefano V, Rispoli MG, Pellegrino N, Graziosi A, Rotondo E, Napoli C, et al. Diagnostic and therapeutic aspects of hemiplegic migraine. J Neurol Neurosurg Psychiatry. 2020;91:76471. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA. 1983;250:25002. <\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology. 2003;60:1201. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Petersen AS, Barloese MCJ, Snoer A, Soerensen AMS, Jensen RH. Verapamil and cluster headache: still a mystery. a narrative review of efficacy, mechanisms and perspectives. Headache. 2019;59:1198211. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Gabai IJ, Spierings EL. Prophylactic treatment of cluster headache with verapamil. Headache. 1989;29:1678. <\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Jnsdttir M, Meyer JS, Rogers RL. Efficacy, side effects and tolerance compared during headache treatment with three different calcium blockers. Headache. 1987;27:3649. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Fotuhi M, Glaun B, Quan SY, Sofare T. Vestibular migraine: a critical review of treatment trials. J Neurol. 2009;256:7116. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Pomes LM, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P. Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019;20:56. <\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Cutrer FM, Moyer AM, Atkinson EJ, Wang L, Tian S, Wu Y, et al. Genetic variants related to successful migraine prophylaxis with verapamil. Mol Genet Genomic Med. 2021;9:e1680. <\/p>\n
Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharm. 1995;353:11621. <\/p>\n
Article CAS Google Scholar <\/p>\n
Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, et al. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharm Ther. 2007;82:57985. <\/p>\n
Article CAS Google Scholar <\/p>\n
Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharm. 1993;348:3327. <\/p>\n
Article CAS Google Scholar <\/p>\n
Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharm. 1999;47:54552. <\/p>\n
Article CAS Google Scholar <\/p>\n
Zhao LM, He XJ, Qiu F, Sun YX, Li-Ling J. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. Br J Clin Pharm. 2009;68:395401. <\/p>\n
Article CAS Google Scholar <\/p>\n
Borlak J, Walles M, Levsen K, Thum T. Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. Drug Metab Dispos. 2003;31:88891. <\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of Cytochrome P450 Alleles: A meta-analysis of population-scale sequencing projects. Clin Pharm Ther. 2017;102:688700. <\/p>\n
Article CAS Google Scholar <\/p>\n
Amitriptyline [package insert]. Prinston, NJ: Sandoz Inc.; 2014. <\/p>\n
PAMELOR (nortriptyline) [package insert]. Hazelwood, MO: Mallinckrodt Pharmaceuticals; 2019. <\/p>\n
EFFEXOR XR (venlafaxine) [package insert]. Philadelphia, PA: Pfizer; 2021. <\/p>\n
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Mller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharm Ther. 2017;102:3744. <\/p>\n
Article CAS Google Scholar <\/p>\n
Jiang F, Kim HD, Na HS, Lee SY, Seo DW, Choi JY, et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Psychopharmacology. 2015;232:1899909. <\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
The Royal Dutch Pharmacists Association-Pharmacogenetics Working Group (DPWG). Dutch guidelines August 2019 update. <\/p>\n
CALAN SR (verapamil) [package insert]. New York, NY: Pfizer; 2019. <\/p>\n
Fuhr U, Mller-Peltzer H, Kern R, Lopez-Rojas P, Jnemann M, Harder S, et al. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharm. 2002;58:4553. <\/p>\n
Article CAS Google Scholar <\/p>\n
Benowitz NL, Peng M, Jacob P 3rd. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharm Ther. 2003;74:46874. <\/p>\n
Article CAS Google Scholar <\/p>\n
Bauer M, Karch R, Zeitlinger M, Philippe C, Rmermann K, Stanek J, et al. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. J Cereb Blood Flow Metab. 2015;35:7436. <\/p>\n
Article CAS PubMed PubMed Central Google Scholar <\/p>\n
Eriksen MK, Thomsen LL, Olesen J. Sensitivity and specificity of the new international diagnostic criteria for migraine with aura. J Neurol Neurosurg Psychiatry. 2005;76:2127. <\/p>\n
Article CAS PubMed PubMed Central Google Scholar <\/p>\n
Kelman L. The aura: a tertiary care study of 952 migraine patients. Cephalalgia. 2004;24:72834. <\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
<\/p>\n
Read the rest here: Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Continue reading
\nPharmacogenomic studyA pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of ... - Nature.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"